ABL503 for Solid Tumors

USC, Los Angeles, CA
Solid TumorsABL503 - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new cancer drug to see if it is safe and effective.

Eligible Conditions
  • Advanced Solid Tumors

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 1

Study Objectives

2 Primary · 3 Secondary · Reporting Duration: From Day 1 until disease progression or Day 28, whichever came first

Month 12
Immunogenicity of ABL503
Number of subjects with AE, IrAEs, IRRs, SAEs and abnormalities in Lab
Objective Response Rate (ORR)
Pharmacokinetic (PK) of ABL503
Day 28
Number of Subjects with Dose-Limiting Toxicities (DLT)

Trial Safety

Phase-Based Safety

1 of 3

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

1 Treatment Group

1 of 1

Experimental Treatment

36 Total Participants · 1 Treatment Group

Primary Treatment: ABL503 · No Placebo Group · Phase 1

Experimental Group · 1 Intervention: ABL503 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: from day 1 until disease progression or day 28, whichever came first

Who is running the clinical trial?

ABL Bio, Inc.Lead Sponsor
4 Previous Clinical Trials
213 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a form of cancer that has spread and is getting worse despite previous treatments, or there are no other standard treatments available for your type of cancer.

Frequently Asked Questions

How many participants have been accepted into this scientific experiment?

"To complete the research at hand, 36 suitable candidates must take part in this experiment. People can sign up through NEXT Oncology, located in San Antonio Texas or Sarah Cannon Research Institute at HealthONE which is found in Denver Colorado." - Anonymous Online Contributor

Unverified Answer

Is this clinical research endeavor currently recruiting participants?

"Correct. According to clinicaltrials.gov, this medical study began recruiting participants on April 1st 2021 and is presently seeking volunteers for enrollment. The investigation requires 36 individuals from 5 distinct healthcare facilities." - Anonymous Online Contributor

Unverified Answer

How hazardous is ABL503 for human consumption?

"Since ABL503 is only in its inaugural trial, the safety rating was evaluated as a 1 due to limited evidence of efficacy and security." - Anonymous Online Contributor

Unverified Answer

Are there any hospitals in North America conducting this research initiative?

"Patients have the option of enrolling in this trial at 5 separate medical facilities: NEXT Oncology, Sarah Cannon Research Institute, City of Hope Duarte and 2 other sites." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.